NASDAQ:QTTB Q32 Bio Q4 2024 Earnings Report $15.75 -0.09 (-0.57%) As of 02:03 PM Eastern ProfileEarnings HistoryForecast Q32 Bio EPS ResultsActual EPS-$1.16Consensus EPS -$1.25Beat/MissBeat by +$0.09One Year Ago EPSN/AQ32 Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQ32 Bio Announcement DetailsQuarterQ4 2024Date3/11/2025TimeBefore Market OpensConference Call DateTuesday, March 11, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Q32 Bio Earnings HeadlinesQ32 Bio Inc. (NASDAQ:QTTB) Receives $30.00 Average Price Target from BrokeragesAugust 11, 2026 | americanbankingnews.comHC Wainwright Issues Positive Estimate for Q32 Bio EarningsAugust 9, 2026 | americanbankingnews.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.August 20 at 1:00 AM | Golden Portfolio (Ad)Q32 Bio tops estimates as alopecia drug advances toward late-stage trialsAugust 6, 2026 | seekingalpha.comQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 5, 2026 | prnewswire.comQ32 Bio: Bempikibart's Progress Keeps Me BullishJuly 17, 2026 | seekingalpha.comSee More Q32 Bio Headlines About Q32 BioQ32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.View Q32 Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineAnalog Devices’ AI Pivot Could Push Shares to Fresh HighsViking Stock Fell After Earnings, But the Numbers Tell a Different StoryTJX Companies Stock Drop Sets Up Buy Signal as Analysts Stay BullishTarget Is Winning Shoppers Back—Can the Rally Reach $180?Why Lowe’s Could Be a Bargain Before Housing RecoversIs Apple’s AI Strategy Smarter Than Skeptics Think? Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
